This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 1 for:    attest-2
Previous Study | Return to List | Next Study

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST2)

This study is not yet open for participant recruitment.
See Contacts and Locations
Verified September 2016 by NHS Greater Glasgow and Clyde
Sponsor:
Collaborators:
University of Glasgow
University of Edinburgh
Oxford University Hospitals NHS Trust
Information provided by (Responsible Party):
NHS Greater Glasgow and Clyde
ClinicalTrials.gov Identifier:
NCT02814409
First received: June 23, 2016
Last updated: September 21, 2016
Last verified: September 2016
  Purpose
The principle research question is: in patients with acute ischaemic stroke eligible for intravenous (IV) thrombolysis, is tenecteplase superior in efficacy to alteplase, based on functional outcome as assessed by modified Rankin Scale distribution at day 90?

Condition Intervention Phase
Ischemic Stroke Drug: Intravenous recombinant tissue plasminogen activator (rtPA) Alteplase Drug: Intravenous Tenecteplase Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

Resource links provided by NLM:


Further study details as provided by NHS Greater Glasgow and Clyde:

Primary Outcome Measures:
  • modified Rankin Scale [ Time Frame: Day 90 (+/- 7) ]
    modified Rankin Scale (mRS) at day 90, determined by the Rankin Focused Assessment (RFA) method using centralised telephone interview, analysed by ordinal distribution ("shift") analysis of the scores in intervention and control groups.


Secondary Outcome Measures:
  • Full neurological recovery (modified Rankin Scale 0-1 versus 2-6). [ Time Frame: Day 90 (+/- 7) ]
  • Independent recovery (modified Rankin Scale score 0-2 versus 3-6). [ Time Frame: Day 90 (+/- 7) ]
  • Early major neurological improvement of 8 or more points, or return to the National Institutes of Health Stroke Scale (NIHSS) total score of 0 or 1 at 24 hour(s). [ Time Frame: 24 hours ]
  • Health Related Quality of Life (EuroQol five dimensions questionnaire, EQ-5D) [ Time Frame: Day 90 (+/- 7) ]
  • Barthel Index score [ Time Frame: Day 90 (+/- 7) ]

Other Outcome Measures:
  • Mortality [ Time Frame: Day 90 (+/- 7) ]
  • Imaging scan up to 36 hours, combined with a neurological deterioration NIHSS≥4 points from baseline (or lowest NIHSS value baseline-24 h), or leading to death (Safe Implementation of Thrombolysis in Stroke-Monitoring study definition). [ Time Frame: 36 hours ]
  • Symptomatic Intra-Cerebral Haemorrhage (SICH) by (European Cooperative Acute Stroke Study) ECASS-2 and ECASS-3 definitions. [ Time Frame: up to day 90 ]
  • Parenchymal Haematoma type 2 (PH2) haemorrhage on post-treatment computerised tomography (CT) scan up to 36 hours after treatment. [ Time Frame: 36 hours ]
  • Intracranial haemorrhage [ Time Frame: 22-36 hours ]
    Any intracranial haemorrhage on 22-36 hours computerised tomography (CT) scan

  • Significant extracranial haemorrhage (requirement for blood transfusion or drop in haemoglobin of ≥20mg/l in the 36h after treatment). [ Time Frame: 36 hours ]

Estimated Enrollment: 1870
Study Start Date: October 2016
Estimated Study Completion Date: August 2019
Estimated Primary Completion Date: August 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Alteplase - standard care
Alteplase 0.9 mg/kg with 10% of the total dose administered as an initial intravenous bolus and remaining 90% of the total dose administered as an intravenous infusion over 1 hour (maximum dose 90mg).
Drug: Intravenous recombinant tissue plasminogen activator (rtPA) Alteplase
Experimental: Tenecteplase
Tenecteplase 0.25mg/kg administered as a single rapid intravenous bolus (maximum dose 25mg).
Drug: Intravenous Tenecteplase

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Eligible for intravenous thrombolysis.
  • Male or non-pregnant female ≥18 years of age.
  • <4.5h after symptom onset.
  • Consent of patient or legal representative.
  • Independent prior to the stroke (estimated modified Rankin Scale 0-1).

Exclusion criteria:

  • Eligible for intravenous thrombolysis: Evidence of intracranial haemorrhage or significant non-stroke intracranial pathology likely to account for clinical presentation or represent a risk of intracerebral haemorrhage (eg Central Nervous System neoplasm) on pre-treatment computerised tomography (CT) scan; Stroke within the previous 14 days, thrombolytic therapy within the past 14 days, or hypodensity on pre-treatment computerised tomography (CT) scan consistent with recent cerebral ischaemia other than the presenting event; Systolic blood pressure more than 185 or diastolic blood pressure more than 110 mmHg, or aggressive management (intravenous pharmacotherapy) necessary to reduce blood pressure to these limits; Clinical history suggestive of subarachnoid haemorrhage even if no blood is evident on computerised tomography (CT) scan; High risk of haemorrhage, including major surgery, trauma or gastrointestinal or urinary tract haemorrhage within the previous 21 days; Arterial puncture at a non-compressible site within the previous 7 days; Prolonged cardiopulmonary resuscitation (> 2 minutes) within the previous 14 days; Acute pericarditis and/or subacute bacterial endocarditis; acute pancreatitis; Severe hepatic dysfunction, including hepatic failure, cirrhosis, portal hypertension (oesophageal varices) and active hepatitis; Active peptic ulceration; Known history of haemorrhagic stroke; Known defect of clotting or platelet function (other than antiplatelet therapy); Hypo- or hyperglycaemia (blood glucose <2 mmol/l or >18 mmol/l) sufficient to account for neurological symptoms; Seizure at onset of symptoms unless brain imaging identifies positive evidence of significant brain ischaemia (eg early ischaemic change or hyperdense vessel on plain computerised tomography (CT) scan, computerised tomography angiography (CTA) scan confirmed arterial occlusion); Pregnancy (for women of child-bearing potential a negative pregnancy test will be required prior to randomisation); Inadequate haemostasis: Taking warfarin and international normalised ratio (INR) >1.3, Taking a Direct Oral Anticoagulant (dabigatran, rivaroxaban, apixaban, edoxaban) unless known to be >12 hours since last dose and with normal coagulation assays, Low molecular weight heparin (at doses other than prophylaxis of venous thromboembolism) administered within the preceding 48 hours, Unfractionated heparin administered within the previous 48 hours and activated partial thromboplastin time (APTT) is prolonged.
  • Acute endovascular treatment for stroke planned.
  • Any major medical condition likely to limit survival to day 90.
  • Unavailable for day 90 follow-up.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02814409

Contacts
Contact: Alicia Murray, BSc, PhD Alicia.Murray@glasgow.ac.uk

Sponsors and Collaborators
NHS Greater Glasgow and Clyde
University of Glasgow
University of Edinburgh
Oxford University Hospitals NHS Trust
Investigators
Principal Investigator: Keith Muir, MD, FRCP University of Glasgow
  More Information

Responsible Party: NHS Greater Glasgow and Clyde
ClinicalTrials.gov Identifier: NCT02814409     History of Changes
Other Study ID Numbers: NorthGlasgowU
Study First Received: June 23, 2016
Last Updated: September 21, 2016
Individual Participant Data  
Plan to Share IPD: No

Additional relevant MeSH terms:
Stroke
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Tissue Plasminogen Activator
Plasminogen
Tenecteplase
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on June 28, 2017